Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.

Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.

Item
http://www.wikidata.org/entity/Q34797932
Prognostic molecular markers in early breast cancerRole of tumor associated macrophages in tumor angiogenesis and lymphangiogenesisInvestigation of serum proteome alterations in human glioblastoma multiforme.Tumor markers: from laboratory to clinical utility.Non-invasive proteomics-thinking about personalized breast cancer screening and treatmentTumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms.Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer.Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expressionMolecular and clinicopathological markers of prognosis in breast cancer.Parathyroid hormone-related protein regulates tumor-relevant genes in breast cancer cells.Transforming growth factor-beta1 produced by ovarian cancer cell line HRA stimulates attachment and invasion through an up-regulation of plasminogen activator inhibitor type-1 in human peritoneal mesothelial cells.The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas.Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance.Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents.Platelet count as a predictor of metastasis and venous thromboembolism in patients with cancer.Assessing Tumor Angiogenesis in Histological Samples.Lack of association between level of Plasminogen Activator Inhibitor-1 and estimates of tumor angiogenesis in early breast cancer
P2860

Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.

Item
http://www.wikidata.org/entity/Q34797932
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Clinical utility of urokinase- ...... dividualized therapy concepts.
@ast
Clinical utility of urokinase- ...... dividualized therapy concepts.
@en
Clinical utility of urokinase- ...... dividualized therapy concepts.
@nl
type
label
Clinical utility of urokinase- ...... dividualized therapy concepts.
@ast
Clinical utility of urokinase- ...... dividualized therapy concepts.
@en
Clinical utility of urokinase- ...... dividualized therapy concepts.
@nl
prefLabel
Clinical utility of urokinase- ...... dividualized therapy concepts.
@ast
Clinical utility of urokinase- ...... dividualized therapy concepts.
@en
Clinical utility of urokinase- ...... dividualized therapy concepts.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P356
P1433
P1476
Clinical utility of urokinase- ...... dividualized therapy concepts.
@en
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698